LipidDB ID

LipidDB-9606-01447

Entry Name

UniProt Accession

P08588; B0LPE2; Q5T5Y4; Q9UKG7; Q9UKG8;

Theoretical PI

9.23

Molecular Weight

51322.85

Genbank Protein ID

AAA51667.1; AAD53696.1; AAD53697.1; AAS66983.1; ABY87521.1; CAI16920.1;

Genbank Nucleotide ID

J03019; AF169006; AF169007; AY567837; EU332832; AL355543;

Protein Name

Beta-1 adrenergic receptor

Protein Synonyms/Alias

Beta-1 adrenoreceptor; Beta-1 adrenoceptor;

Gene Name

ADRB1

Gene Synonyms/Alias

ADRB1R; B1AR;

Created Date

01-AUG-1988

Organism

Homo sapiens (Human)

NCBI Taxa ID

9606

Reference

[1] Zuckerman DM, Hicks SW, Charron G, Hang HC, Machamer CE. Differentialregulation of two palmitoylation sites in the cytoplasmic tail of thebeta1-adrenergic receptor. J Biol Chem. 2011 May 27;286(21):19014-23. doi:10.1074/jbc.M110.189977. Epub 2011 Apr 4.[PMID:21464135]

Functional Description

Beta-adrenergic receptors mediate the catecholamine- induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.

Sequence Annotation

Topological domain: 1 55 Extracellular.
Transmembrane: 56 84 Helical; Name=1.
Topological domain: 85 93 Cytoplasmic.
Transmembrane: 94 120 Helical; Name=2.
Topological domain: 121 132 Extracellular.
Transmembrane: 133 154 Helical; Name=3.
Topological domain: 155 172 Cytoplasmic.
Transmembrane: 173 196 Helical; Name=4.
Topological domain: 197 222 Extracellular.
Transmembrane: 223 248 Helical; Name=5.
Topological domain: 249 319 Cytoplasmic.
Transmembrane: 320 349 Helical; Name=6.
Topological domain: 350 354 Extracellular.
Transmembrane: 355 377 Helical; Name=7.
Topological domain: 378 477 Cytoplasmic.
Region: 218 232 Agonist and antagonist binding.
Region: 337 344 Agonist and antagonist binding.
Region: 363 367 Agonist and antagonist binding.
Motif: 474 477 PDZ-Binding.
Binding site: 138 138 Agonist or antagonist.
Binding site: 143 143 Agonist or antagonist.
Modified residue: 312 312 Phosphoserine; by PKA.
Modified residue: 412 412 Phosphoserine; by PKA.

Protein Length

477 AA.

Protein Sequence
(Canonical)

FASTA
(Canonical)

Gene Ontology

GO:0005769; C:early endosome; IDA:UniProtKB
GO:0005887; C:integral component of plasma membrane; TAS:ProtInc
GO:0005634; C:nucleus; IEA:Ensembl
GO:0005886; C:plasma membrane; IDA:UniProtKB
GO:0031694; F:alpha-2A adrenergic receptor binding; IPI:BHF-UCL
GO:0004939; F:beta-adrenergic receptor activity; TAS:ProtInc
GO:0004940; F:beta1-adrenergic receptor activity; TAS:ProtInc
GO:0035240; F:dopamine binding; IEA:Ensembl
GO:0008144; F:drug binding; IEA:Ensembl
GO:0051379; F:epinephrine binding; IEA:Ensembl
GO:0051380; F:norepinephrine binding; IEA:Ensembl
GO:0030165; F:PDZ domain binding; IPI:UniProtKB
GO:0046982; F:protein heterodimerization activity; IPI:BHF-UCL
GO:0005088; F:Ras guanyl-nucleotide exchange factor activity; IDA:UniProtKB
GO:0005057; F:receptor signaling protein activity; IDA:UniProtKB
GO:0007190; P:activation of adenylate cyclase activity; TAS:ProtInc
GO:0071880; P:adenylate cyclase-activating adrenergic receptor signaling pathway; IDA:UniProtKB
GO:0007568; P:aging; IEA:Ensembl
GO:0006915; P:apoptotic process; IEA:Ensembl
GO:0050873; P:brown fat cell differentiation; IEA:Ensembl
GO:0002024; P:diet induced thermogenesis; IEA:Ensembl
GO:0042596; P:fear response; IEA:Ensembl
GO:0005980; P:glycogen catabolic process; IEA:Ensembl
GO:0031649; P:heat generation; IEA:Ensembl
GO:0055088; P:lipid homeostasis; IEA:Ensembl
GO:0007613; P:memory; IEA:Ensembl
GO:0040015; P:negative regulation of multicellular organism growth; IEA:Ensembl
GO:0045986; P:negative regulation of smooth muscle contraction; IEA:Ensembl
GO:0035811; P:negative regulation of urine volume; IEA:Ensembl
GO:0043065; P:positive regulation of apoptotic process; IEA:Ensembl
GO:0030819; P:positive regulation of cAMP biosynthetic process; IDA:UniProtKB
GO:0043950; P:positive regulation of cAMP-mediated signaling; IDA:UniProtKB
GO:2001259; P:positive regulation of cation channel activity; IEA:Ensembl
GO:0061051; P:positive regulation of cell growth involved in cardiac muscle cell development; IEA:Ensembl
GO:0001996; P:positive regulation of heart rate by epinephrine-norepinephrine; IEA:Ensembl
GO:0032320; P:positive regulation of Ras GTPase activity; IDA:UniProtKB
GO:1900135; P:positive regulation of renin secretion into blood stream; IEA:Ensembl
GO:0046878; P:positive regulation of saliva secretion; IEA:Ensembl
GO:0003084; P:positive regulation of systemic arterial blood pressure; IEA:Ensembl
GO:0003061; P:positive regulation of the force of heart contraction by norepinephrine; IEA:Ensembl
GO:0033365; P:protein localization to organelle; IEA:Ensembl
GO:0051924; P:regulation of calcium ion transport; IEA:Ensembl
GO:0086004; P:regulation of cardiac muscle cell contraction; IEA:Ensembl
GO:0060080; P:regulation of inhibitory postsynaptic membrane potential; IEA:Ensembl
GO:0009409; P:response to cold; IEA:Ensembl
GO:0007266; P:Rho protein signal transduction; IEA:Ensembl
GO:0019233; P:sensory perception of pain; IEA:Ensembl
GO:0002025; P:vasodilation by norepinephrine-epinephrine involved in regulation of systemic arterial blood pressure; IEA:Ensembl
GO:0042060; P:wound healing; IEA:Ensembl

Interpro

InterPro; IPR002233; ADR_fam
InterPro; IPR000507; ADRB1_rcpt
InterPro; IPR000276; GPCR_Rhodpsn
InterPro; IPR017452; GPCR_Rhodpsn_7TM

Pfam

Pfam; PF00001; 7tm_1;

SMART

PROSITE

PROSITE; PS00237; G_PROTEIN_RECEP_F1_1;
PROSITE; PS50262; G_PROTEIN_RECEP_F1_2;

PRINTS

PRINTS; PR01103; ADRENERGICR;
PRINTS; PR00561; ADRENRGCB1AR;
PRINTS; PR00237; GPCRRHODOPSN;